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Abstract 
Delayed sleep phase disorder (DSPD) is a circadian rhythm sleep disorder. Patients with DSPD have 
problems initiating sleep if they go to bed at a conventional time and they often have problems waking at 
desired times. If they rise early in the morning they usually experience severe sleepiness during morning 
hours. In the present study we investigated short- and long term effects on measures of subjective and 
objective sleepiness and cognitive function of bright light and melatonin treatment alongside gradually 
advanced rise times in adolescents and young adults. Four treatment conditions were used in the short-
term intervention (two weeks); dim light (placebo) + placebo capsule, bright light + placebo capsule, dim 
light (placebo) + melatonin capsule and bright light + melatonin capsule. This was followed by a long-
term intervention (three months) including two conditions; no treatment and combined bright light + 
melatonin treatment. Effects of treatment on sleepiness and fatigue were the primary outcome measures 
and effects on cognitive function were secondary outcome measures. On a gradual advancement of rise 
time schedule, all treatment conditions (bright light, melatonin, the combination and placebo) were almost 
equally effective in improving subjective daytime sleepiness, fatigue and cognitive function in the two-
week study. The two-week intervention showed no effect on objective sleepiness. Long-term treatment 
increased some of the positive effects seen after two weeks. Combined bright light and melatonin 
treatment improved subjective daytime sleepiness, fatigue and cognitive function in the three-month 
study. The no-treatment group returned to baseline values on most variables. In conclusion, gradual 
advancement of rise times seems to produce positive effects on subjective sleepiness, fatigue and 
cognitive performance during short-term treatment of patients with DSPD. However, the benefits from 
gradually advanced rise times seem to wear off, suggesting that continuation of bright light and melatonin 
treatment is beneficial to maintain positive effects over time.  
Key words: randomized controlled trial, circadian rhythms, delayed sleep phase disorder, bright light, 
melatonin, treatment, daytime function 
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Delayed sleep phase disorder (DSPD) is a circadian rhythm sleep disorder where the sleep period is 
delayed with respect to conventional norms (American Academy of Sleep Medicine 2005). Patients with 
DSPD have been described as unable to advance their sleep phase by behavioral means (American 
Academy of Sleep Medicine 2005), and the disorder is associated with impairments related to school or 
work functioning, alcohol and substance abuse and psychological and relational disturbances (American 
Academy of Sleep Medicine 2005; Dagan and Eisenstein 1999; Regestein and Monk 1995; Saxvig et al. 
2012). Hence, DSPD is a disorder with several psychosocial challenges (Wilhelmsen-Langeland et al. 
2012). The prevalence of DSPD is estimated to be 7-16% in adolescence (American Academy of Sleep 
Medicine 2005; Gradisar et al. 2011b).  
DSPD does not involve a dysfunction of the sleep period itself, but simply a delay of the 
circadian rhythm (Thorpy et al. 1988; Weitzman et al. 1981). Thus, patients with DSPD have problems 
initiating sleep if they go to bed at a conventional time and they accordingly experience severe sleepiness 
during morning hours (American Academy of Sleep Medicine 2005; Thorpy et al. 1988; Weitzman et al. 
1981). Our research group has previously shown that the sleep architecture itself is not different from 
healthy controls when patients with DSPD are allowed to sleep at self-chosen times (Saxvig et al. 2013b). 
Since the sleep period is delayed in patients with DSPD, they have more slow wave sleep between 6am 
and 8am than controls (Saxvig et al. 2013b). Sleep curtailment typically leads the patients to catch up on 
sleep when they can, i.e. by napping and by extending sleep on weekends and holidays, which only 
maintain and potentially increase the sleep phase delay the following nights (Crowley et al. 2007). 
The effect of sleep deprivation is known to affect cognitive function negatively, but little is 
known about how these functions are influenced in patients with DSPD. Shekleton and colleagues (2010) 
have reviewed studies on neurobehavioral performance in patients with insomnia. The most consistent 
impairment was shown on tests measuring different aspects of attention and executive function, and their 
results called for the inclusion of standard psychometric tests in future studies of sleep disorders 
(Shekleton et al. 2010).  
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Successful advancement of the sleep period and circadian rhythm is expected to reduce or 
eliminate negative consequences such as daytime sleepiness in patients with DSPD (Gradisar et al. 
2011a). Timed bright light exposure and melatonin administration seem to be the most widely used 
treatment options for DSPD in clinical practice (Bjorvatn and Pallesen 2009). The timing of light is 
crucial (Bjorvatn and Pallesen 2009) as light before core body temperature minimum (CTmin) delays the 
circadian rhythm, whereas light after CTmin advances the circadian rhythm (Khalsa et al. 2003). Bright 
light after awakening has proven to be effective in advancing the sleep phase in patients with DSPD 
(Lack et al. 2007; Rosenthal et al. 1990). Rosenthal and colleagues (1990) conducted the only study that 
we know of on patients with DSPD assessing the effects of bright light treatment on objective sleepiness 
(sleep propensity) by the multiple sleep latency test (MSLT) (Carskadon et al. 1986). Their bright light 
group (2500 lux) showed increased sleep latency at 9am and 11am (but not at other times during the day) 
compared to the dim light group (300 lux). Cole and colleagues (2002) found reduced subjective morning 
sleepiness in a bright light group (2700 lux masks) compared to a dim light group (<0.01 lux masks), but 
only in the most delayed subjects. Recently, cognitive behavioral therapy in combination with bright light 
therapy showed promising effects on advancement of the sleep period, subjective sleepiness and fatigue 
in adolescents with DSPD (Gradisar et al. 2011a).  
Similar to the effects of light, the effects of exogenous melatonin administration also follow a 
phase-response curve (Lewy et al. 1998). Previous studies have shown that the sleep period may be 
advanced by use of melatonin in the evening, usually taken a few hours before expected sleep onset 
(Dahlitz et al. 1991; Kayumov et al. 2001; Mundey et al. 2005; Nagtegaal et al. 1998; Rahman et al. 
2010). Only two of these studies included measures of subjective daytime sleepiness/alertness. Dahlitz 
and colleagues (1991) found no changes on self-reported alertness following melatonin treatment. 
Similarly, Kayumov and colleagues (2001) found no overall difference on measures of subjective 
sleepiness, fatigue and alertness between a melatonin and a placebo group. However, when adhering to an 
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imposed sleep schedule (midnight to 8am), subjects taking melatonin were less sleepy and fatigued than 
the placebo group.   
There is currently not sufficient empirical evidence to recommend specific treatment guidelines 
for DSPD (Gradisar et al. 2011a) and more controlled studies are consequently warranted (Bjorvatn and 
Pallesen 2009; Gradisar et al. 2011a; Mundey et al. 2005).Despite the fact that DSPD is most common in 
adolescence and young adulthood, we only know of one treatment study on adolescents with DSPD 
(Gradisar et al. 2011a). In the present study we investigated short- and long-term effects on subjective and 
objective sleepiness and cognitive function of bright light and melatonin treatment alongside gradually 
advanced rise times in adolescents and young adults. The treatment protocol was designed based on 
knowledge of the advancing effects of melatonin and bright light on the circadian rhythm when timed 
correctly. The treatment protocol in the present study has been used for many years in clinical practice by 
some of the co-authors and is described in detail in a review (Bjorvatn and Pallesen 2009). The effects of 
four short-term treatment conditions were investigated; dim light (placebo)+ placebo capsule, bright light 
+ placebo capsule, dim light (placebo)+ melatonin capsule and bright light + melatonin capsule. This was 
followed by a long-term intervention (approximately three months duration) including two conditions; no 
treatment and combined bright light + melatonin. In the present study we investigated the effect of 
treatment on subjective and objective daytime function (on a simulated real-life school/work-setting 
starting at 8am), with sleepiness and fatigue as primary outcomes and cognitive function as secondary 
outcome. Sleep data (sleep diary, actigraphy and DLMO) were also collected, but are described in another 
article (Saxvig et al., 2013a).  
 
Methods 
Participants 
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The participants were recruited to take part in a clinical trial (http://www.clinicaltrials.gov/: 
NCT00834886) through advertisements at high schools, a college and a university (i.e. e-mails, flyers, 
posters and stands) and in relevant media. A link to a study website was distributed, which contained 
information about the disorder, the study protocol and contact information.  
 
Inclusion/exclusion criteria 
Inclusion criteria were 1) living in Bergen, Norway, 2) age 16-25 years, 3) good general health as 
specified by the exclusion criteria (see below) and 4) fulfilling the diagnostic criteria for DSPD. The 
participants were diagnosed according to the criteria found in the International Classification of Sleep 
Disorders, 2nd version (ICSD-2) (American Academy of Sleep Medicine 2005), operationalized for this 
study as: 1) problems falling asleep in the evening, 2) falling asleep after 2 am at least 3 days a week, 3) 
ability to sleep until early afternoon, 4) problems waking up in time for school/work, 5) early wake-up 
times associated with extreme daytime sleepiness, 6) good subjective sleep quality and duration when 
given the opportunity to sleep at self-chosen times and 7) self-reporting verbally the aforementioned sleep 
problems as chronic (>6 months).The DSPD diagnosis was confirmed as required by the ICSD-2 criteria 
by sleep diary data covering a one week period showing a delayed sleep pattern. 
Exclusion criteria were sleep disorders other than DSPD, moderate to severe psychopathology 
(see later for procedure), conditions assumed to affect sleep (i.e. migraine, B12 deficiency), all serious 
somatic disorders (i.e. rheumatoid arthritis, diabetes), medications or treatments assumed to affect sleep 
(i.e. sedative anti-histamines, antidepressants, hypnotics), substance abuse, night work, IQ < 70, breast 
feeding and pregnancy.  
A total of 264 potential participants responded to the initial invitation. In total, 60 persons 
fulfilled the basic criteria for inclusion and were scheduled for a meeting. Of those, 10 withdrew prior to 
the scheduled meeting. The remaining 50 potential participants were screened with the Structured Clinical 
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Interview for DSM-IV (SCID-I) diagnoses (First et al. 1997), the IQ-test Raven`s Progressive Matrices 
(Raven 2000) and pregnancy test (only females) and further set up for a polysomnographic screening 
(PSG). A total of 40 participants (see Figure 1 for withdrawal/exclusion categories) were included and 
successively randomized for participation. Neither of the participants had ever before been diagnosed 
with DSPD nor had they previously received treatment for DSPD. Inclusion and data collection were 
performed from the fall of 2008 until early 2012. Figure 1 illustrates the participant flow throughout the 
study. 
 
INSERT Figure 1 
 
Ethics  
Informed consent was obtained after a full explanation of the study protocol. For participants under 18 
years of age, parents were required to sign the consent form before inclusion and to give verbal consent. 
All participants received a compensation fee (approximately 80$ USD) for their time invested in the 
study. The study was approved by the Regional Committee for Medical and Health Research Ethics in 
Western Norway, the Norwegian Social Data Service and the Norwegian Medicines Agency. 
 
Setting and facilities   
All meetings with participants took place at the sleep laboratory at the Faculty of Psychology, University 
of Bergen. Inclusion meetings took place between 8am and 5pm, the polysomnography hook-up took 
place between 6pm and 1130pm.All daytime testing protocol meetings started 8-830am and ended about 
2-3pm. Lighting conditions in the testing rooms were 200 lux. Light was set to 500 lux in the laboratory 
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where participants stayed during breaks. The laboratory had no windows. Hence, participants were not 
exposed to daylight while being tested. Although there are seasonal variations in daylight in Norway, 
these variations are likely to be spread across the sample and should consequently not influence the 
results. The first author (AWL) and co-author IWS administrated all tasks throughout the study (with help 
from a research assistant, co-author ØV).  
 
Instruments 
Demographic information 
Data were collected regarding age, gender, self-reported average school grades, intelligence (Raven 
2000), symptoms of anxiety and depression (Zigmond and Snaith 1983), school/employment status (high 
school or college/university students, employed or unemployed), living conditions (with or without their 
parents), bed time and rise time.  
 
Subjective self-evaluations of sleepiness and fatigue 
The Karolinska Sleepiness Scale (KSS) (Åkerstedt and Gillberg 1990) is a scale where subjects rate their 
concurrent sleepiness level. The scale is verbally anchored with steps ranging from 1 (“very alert”) to 9 
(“very sleepy, fighting sleep, effort to stay awake”). The Epworth Sleepiness Scale (ESS) (Johns 1991) is 
a questionnaire providing a trait measure of daytime sleepiness. The subject rates the probability of 
falling asleep/dozing off in eight different everyday situations on a scale ranging from 0 (no probability) 
to 3 (high probability). We used the validated Norwegian version of the ESS (Pallesen et al. 2007). For 
the Fatigue Questionnaire (FQ) (Chalder et al. 1993), we used a total fatigue score that was generated 
from 7 items related to physical fatigue and 4 items related to mental fatigue. We administered the 
validated Norwegian version of the FQ (Loge et al. 1998). 
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Objective sleepiness (arousal) 
The Alpha Attenuation Test (AAT) is a quantitative method for assessing objective sleepiness. It is 
developed based on the fact that the EEG power spectrum in the alpha frequency band increases with eyes 
open and decreases with eyes closed as the participant becomes sleepier (Stampi 1995). The participants 
were instructed to sit comfortably in an office chair in a sound proof chamber, to relax but to remain 
awake and to look at a red “X” on the wall straight ahead of them. They were asked to close their eyes 
and to open their eyes consecutively at two-minute intervals, three times. Thus, the total duration of the 
AAT was 12 minutes. Electrodes were montaged according to the AASM Manual for the Scoring of 
Sleep and Associated Events (Iber et al. 2007). Data were collected online with ambulatory Embla 
Titanum recorders and the Somnologica software package (Embla Systems Inc., USA). A single EEG 
derivation was used for spectral analyses (O1). Power spectrum analysis criteria were set to: power-bands 
alpha = 8 - 11.99 Hz, 1 second epochs, 256 point fast Fourier transform (FFT) overlapped by 0%, where 
the FFT`s are averaged with the selected epoch duration. We divided the average spectral alpha power of 
eyes closed by the average spectral alpha power of eyes open, which gives a ratio of the “alpha 
attenuation coefficient” (AAC) (Stampi 1995). The higher the AAC is, the higher the alertness level is. 
 
Cognitive function 
The present study included a set of standardized psychometric tests to measure aspects of attention and 
executive function. The Conners` Continuous Performance Test (CPT-II) Version 5.1 for Windows® is a 
test of different aspects of attention (Conners and MHS Staff 2004). It lasts 14 minutes. The subject is 
instructed to press the space bar on the computer keyboard whenever a letter appears on the screen, 
except for the letter “X”. The CPT-II is a test assessing the ability to maintain focused alertness over a 
relatively long period of time. In the present study we included an overall reaction time measure (RT for 
hits), two measures of accuracy (number of omission; responses that should have been given but were 
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not) and commissions (wrong responses given when there should be no response) and two measures of 
consistency (Hit RT standard error and Variability). Three subtests from Wechsler Adult Intelligence 
Scale-III (WAIS-III) (Wechsler 1997); the Digit Symbol-, Letter-Number Sequencing- and the Symbol 
Search Test, were included as measures of working memory/processing speed. During the Digit Symbol 
Test, digits and symbols are presented as pairs and additional digits and symbols must be paired by the 
subject. Letter-Number Sequencing requires that the subject order numbers and letters that are presented 
in an unordered sequence. In the Symbol Search Test, the subject must match symbols that appear in 
different groups. Finally, three subtests from the Delis-Kaplan Executive Function System (D-KEFS) 
(Delis et al. 2001) were included as measures of executive function. From the Color Word Interference 
Test (CWIT) we included the third condition, where the subjects are presented color words printed in 
incongruently colored ink (CWIT-Inhibition), and the fourth condition, requiring the subject to switch 
between either naming the color of the incongruently colored color-words or reading the color names 
when presented with a brace (CWIT-Inhibition/Switching). From the Verbal Fluency Test (VFT), we 
included the condition where the subjects are asked  to switch between reporting items from two different 
categories (VFT-Category Switching).  
 
Compliance and side-effects 
A form to be completed each day of the two-week treatment period was developed in order to measure 
compliance for timing/duration of light exposure and if capsule had been taken and at what time. Points 
were given for light exposure (one point), capsule taken (one point) and rise time (one point) at the 
prescribed time (+/- 1 hr). Full score on all measures was rated as 100% compliance. For the three-month 
follow-up, points were given for light exposure (yes=one point) and melatonin capsule taken (yes=one 
point). Full score was rated as 100% compliance. Side-effects during treatment were retrospectively 
recorded at the two-week assessment (participants noted any possible side-effects on a form developed 
for the study) and at three-month follow-up. In cases of adverse events, guidelines for Good Clinical 
Practice (GCP) were followed (Switula 2000).   
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Procedure/design 
Participants underwent the same daytime testing protocol at three assessment points: before treatment 
(baseline assessment), after two-week treatment (two-week assessment) and after three months of 
treatment/no-treatment (three month assessment). Prior to baseline assessment, participants had been 
instructed togo to bed and rise at self-determined times for four consecutive days in order to avoid sleep 
deprivation. On the assessment days, the participants were instructed to rise at 7am and to meet at the 
sleep laboratory at 8am. Test sessions started about every hour from 9am to about 1pm with intermediate 
breaks, with the purpose of simulating a typical day at school or a day at work (between 8am and 9am the 
participants had breakfast and electrodes for the AAT were montaged). The AAT, KSS and CPT-II were 
all administered three times each assessment day, in the mentioned order, at approximately 9am, 11am 
and 1pm. All other tests were administered once. The protocol included measures of  subjective 
sleepiness and fatigue (KSS, ESS and FQ), objective sleepiness/arousal (AAT) and performance on tests 
of cognitive function (CPT-II, WAIS-III subtests and D-KEFS subtests).   
Participants were randomized into one of four treatment conditions lasting for two weeks in a 
double-blinded, placebo controlled design. The four treatment conditions were: dim light (placebo) and 
placebo capsules (placebo group), bright light and placebo capsules (bright light group), dim light 
(placebo) and melatonin capsules (melatonin group) and bright light and melatonin capsules (combination 
group). All groups were instructed to use dim/bright light and placebo/melatonin capsules on a gradual 
advancement schedule regarding rise times and treatment times. In a follow-up study, participants were 
re-randomized into two groups receiving either the treatment combination of bright light and melatonin 
alongside gradually advanced rise times (treatment group) or no treatment (no-treatment group) in an 
open label trial for approximately three months.  
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Treatment protocol 
The treatment protocol was based on the approach described by Bjorvatn and Pallesen (2009). The 
participants were instructed to sleep until spontaneous awakening on the first day of treatment and then to 
expose themselves to the study light source for 30 to 45 minutes immediately after awakening, with eyes 
directed towards the lamp. Melatonin/placebo capsules were to be taken 12 hours after light treatment 
exposure was initiated. Because of the soporific effects of melatonin, capsules were not to be taken before 
8pm in the evening. This instruction ensured that treatment was individualized according to how delayed 
each participant’s circadian rhythm was. Rise time was advanced by one hour every day until the 
preferred rise time was reached (each participant chose their target rise time) and then maintained until 
the end of the two-week treatment period. If the participant overslept, the instructions were to be exposed 
to the study light lamp immediately upon awakening, to take a capsule 12 hours later and then advance by 
one hour every day until target rise time. No instructions were provided regarding bedtime. Alcohol usage 
was prohibited during the two-week treatment period; no instructions regarding alcohol use were given 
during the three-month follow-up study.  
 
Bright white light and dim red light 
Light lamps were ML-10 000 manufactured by Miljølys Inc., Norway. ML-10 000 is a light box (47 x 
17.5 x 29 cm) containing three fluorescent bulbs (Philips, Ecotone, P1-L, RA-index=80, light temperature 
4000 K). Lamplights were either bright white (approximately 10 000 lux at 50 cm distance) with a clear 
cover screen or dim (approximately 400 lux at 50 cm distance) with a red cover screen. Dim light lamps 
are traditionally assumed to have minimal effect on the endogenous circadian rhythm (Lewy et al. 1980) 
and dim light (300 lux) was used as the control condition in the study by Rosenthal and colleagues 
(1990), who found superior effects in their active condition (2500 lux).  
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Melatonin capsules and placebo capsules 
Hard capsules were packed by Kragerø Tablettproduksjon Inc., Norway, for the two-week intervention, 
and contained either fast release melatonin (5-methoxy-N-acetyltryptamine) 3 mg or 3 mg of Maydis 
Amylum (maize starch). Melatonin was purchased from Nature’s One, Asaman Inc., USA 
(www.asaman.com). We used the original capsules of 3 mg from Nature`s One for the three-month 
follow-up study.  
 
Blinding 
The two-week treatment study was double-blinded. Participants were informed that they would receive 
either red or white light, but not that the light intensity was different. Lamps were given to the 
participants packed in boxes concealing the color of the cover screen differentiated by a letter code (A 
and B) and the participants were instructed not to reveal the color to the study administrators at any time 
(blinding of light boxes was performed by two university employees not otherwise involved in the study). 
Participants were further informed that the capsules contained either melatonin or maize starch. The 
melatonin and placebo capsules were packed in identical containers differentiated by a number code (1 
and 2). In case of adverse events, those who blinded the lamp boxes, kept the code for the capsules and 
the lamps throughout the data collection period. The three-month follow-up study was not blinded. 
 
Randomization 
The randomization lists were made (four groups for the two-week intervention, two groups for the three-
month follow-up) using the Internet based program Research Randomizer 
(http://www.randomizer.org/form.htm). Participants were chronologically assigned to the respective 
groups on inclusion. 
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Statistical analyses 
Data were analyzed using IBM SPSS Statistics version 19.0. In cases of withdrawal from the study or 
missing data, baseline values were carried forward in an intention to treat analysis to ensure that clinical 
effectiveness was not overestimated (Hollis and Campbell 1999).  
Demographic variables were compared between groups using one-way ANOVA and t-tests for 
independent samples (age, self-reported school grades, intelligence, anxiety, depression, bed time and rise 
time) and Pearson chi square test (gender, high school/university or college, living situation) to 
investigate whether the groups differed on these parameters at baseline. One-way ANOVA was also 
performed on all outcome measures at baseline between the four two-week intervention groups and 
between the two three-month groups.  
Effects of the two-week treatment period were compared between the four groups using two-way 
ANOVA (4 treatment groups x 2 assessment points) for repeated measures of KSS, AAT and CPT-II 
(values at all three sessions; 9am, 11am and 1pm). Only the mean values of the three sessions are 
presented in the tables, because no additional information was provided by analyzing each of them 
separately. Two-way ANOVA for repeated measures between baseline and two-week assessment was 
also performed for the WAIS-III subtests, the D-KEFS subtests and for the questionnaires (ESS and FQ). 
Raw scores (as opposed to scaled scores and t-scores relating to a normative average) were used for 
analysis of all cognitive performance tests (CPT-II, WAIS-III and D-KEFS). For compliance and 
measures of side-effects, one-way ANOVA (percentage of compliance) and chi square test (compliance 
50% = yes/compliance <50% = no; side effect categories; and reported side effects = yes/did not report 
side effects = no) was performed to test for differences between the groups.  
At three-month assessment the same variables were compared between the groups (no-
treatment/treatment) with respect to both the baseline assessment and to the two-week assessment using 
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two-way ANOVA for repeated measures (2 treatment groups x 2 assessment points). Interaction effects 
were further assessed using t-tests for paired samples. Cohen`s d was calculated between baseline and the 
two-week assessment and between baseline and the three-month assessment using an online calculator 
(http://easycalculation.com/statistics/effect-size.php) with the formula: d=M1-M2/(sqrt(SD12+SD22)/2). 
  
Results 
Baseline assessment  
There were no differences in terms of demographic variables between the four groups in the two-week 
treatment study at baseline (Table 1). For the three-month follow-up, participants in the treatment group 
were somewhat older than the participants in the no-treatment group (p=.042) (Table 1). At baseline, 
there were no differences between the two-week groups or the three-month groups on any of the primary 
or secondary outcome measures.  
 
INSERT TABLE 1  
 
Two-week assessment  
Subjective sleepiness and fatigue. At two-week assessment, all groups showed a reduction in subjective 
sleepiness measured with the KSS (p=<.0005). There were no interaction effect and hence no differential 
improvement on the KSS between the four groups (Table 2). Similarly, subjective sleepiness measured by 
the ESS showed effect of time (p=.028). All groups had improved subjective sleepiness measured by ESS 
at two-week assessment compared to baseline, but with no clear significant interaction. All four groups 
were less fatigued at two-week assessment with no interaction effect (Table 2). 
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Objective sleepiness/arousal. There were no differences between baseline and the two-week assessment 
on the AAC (Table 2).  
 
INSERT TABLE 2 
 
Cognitive performance. There was no effect of time or interaction on any of the CPT-II measures for 
reaction time or accuracy. There was an overall improvement over time on all working 
memory/processing speed variables (WAIS-III), but no interaction effect between the 4 groups was found 
(Table 3). There was no effect of time or interaction on CPT-II consistency measures. There was an 
overall improvement with time on all executive function measures (VFT-Category Switching, CWIT-
Inhibition and CWIT Inhibition/switching) across all groups, with no interaction effect (Table 3). 
 
INSERT TABLE 3 
 
Dropouts, compliance and side-effects. Two participants withdrew from the two-week study (see Figure 1 
for explanation). Compliance was 84.5% in the combination group, 77% in the melatonin group, 86.3% in 
the bright light group and 87.3% in the placebo group with no difference between the groups (p=.567). 
One participant in the combination group and two in the melatonin group were rated as non-compliant 
(<50%) (p=.306). Side-effects were reported by 15 participants. Of these 15, six were in the combination 
group, two in the melatonin group, four in the bright light group and three in the placebo group (p=.409). 
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Side-effects reported were headache (5), nausea (3), discomfort in eyes (5) and skin irritation (2). None of 
the side-effects were serious or long-lasting.  
At two-week assessment there was advancement in rise time of almost two and a half hours and 
bedtime of about one hour across all groups, with no interaction effect (Saxvig et al 2013a).   
 
Three-month assessment 
Because there were no interactions differentiating the four treatment conditions at two-week treatment, 
the two-week data were therefore collapsed (two-week groups were combined) when they were used in 
the analysis for the three-month follow-up.     
 
Subjective sleepiness and fatigue. At the three-month follow-up, there was an effect of time (p=<.0005) as 
well as an interaction effect (p=.022) on KSS in favor of the treatment group (Table 4). The treatment 
group reported reduced subjective sleepiness compared to baseline at all three time points (9am, p=.002; 
11am, p=<.0005; and 1pm, p=.013). The no-treatment group did not score differently at three-month 
follow-up compared to baseline on any test session. Subjective sleepiness measured by the ESS showed a 
positive effect of time compared to baseline but no interaction. However, there was both an effect of time 
and an interaction effect when comparing the two-week- to the three-month assessment, revealing that the 
treatment group reduced their score over time (p=<.0005). The no-treatment group did not score 
differently on the ESS at three-month assessment compared to the two-week assessment (p=.180) (Table 
4). There was an effect of time and an interaction effect on fatigue at three-month assessment compared 
to baseline. The treatment group was less fatigued (p=.004), while the no-treatment group scored no 
different from baseline on the fatigue scale (p=.894) (Table 4). 
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Objective sleepiness/arousal. There was no effect of time or interaction between the baseline and three-
month assessment of the AAC (Table 4).  
 
INSERT TABLE 4 
 
Cognitive function. There was an interaction effect on the reaction time measure when comparing three-
month follow-up to baseline (p=.010) and to two-week assessment (p=.011). The effect was due to slower 
RT for hits in the no-treatment group at three-month follow-up compared to baseline and to the two-week 
assessment, while the treatment group did not score differently than baseline at two-week or three-month 
assessment (Table 5). Three-month follow-up data showed that there was an improved effect of time from 
baseline on all working memory/processing speed variables. However, there was no interaction effect. 
There was also improvement over time at three-month follow-up compared to two-week assessment on 
the WAIS-III Digit Symbol Test, with no interaction effect (Table 5). There was an interaction effect on 
the CPT-II consistency measures Hit RT standard error and Variability (Table 5). The treatment group 
scored more consistent than the no-treatment group at three-month assessment compared to baseline. 
There was a positive effect of time on all executive function measures and an interaction effect on the 
VFT-Category Switching. Paired samples t-tests showed that the treatment group had improved their 
performance on VFT-Category Switching while the no-treatment group scored no different from baseline 
(Table 5).     
 
INSERT TABLE 5 
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Dropouts, compliance and side-effects. Three participants withdrew from the three-month follow-up (see 
Figure 1 for explanation). Average compliance was 58% in the treatment group when including 19 
participants (one missing value because compliance was not recorded by one participant). Thirteen 
participants (65%) were rated as compliant to treatment (50%) and seven (35%) as non-compliant 
(<50%). Side-effects were reported by three participants and regarded headache (1) and discomfort in 
eyes (2). Side-effects were not serious or long-lasting.   
Three-month assessment showed an advancement in rise time of about two hours compared to 
baseline and bed-time of more than one hour in the treatment group, whereas the no-treatment group had 
returned to baseline timing of rise time and bedtime (Saxvig et al. 2013a).  
 
Discussion 
Effects of bright light and melatonin administered alongside gradual advancement of rise times were 
investigated using a randomized, double blind, placebo controlled design. After short-term treatment (two 
weeks), subjective sleepiness measured by the KSS was reduced across groups by more than one point 
with large effect sizes. However, there were no differences between the four treatment conditions. Two-
week treatment also yielded reduction in subjective sleepiness in all groups assessed by the ESS, with a 
large effect size for the combination group only, and the treatment also resulted in a reduction on fatigue 
across the four groups. Participants in all four conditions improved their cognitive performance on tests of 
working memory/processing speed and executive function, but not on the reaction time, accuracy and 
consistency measures from the CPT-II. In sum, bright light, melatonin, the combination and placebo 
alongside a gradual advancement schedule were almost equally effective in improving subjective daytime 
sleepiness, fatigue and cognitive function in the two-week study. This contradicts the findings from 
previous studies, where subjective sleepiness, objective sleepiness, fatigue and alertness improved 
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significantly only after active treatment (Gradisar et al. 2011a; Kayumov et al. 2001; Rosenthal et al. 
1990).   
It has been assumed that patients with DSPD can not achieve advancement in sleep-phase 
(leading to reduction in daytime sleepiness) by behavioral means (American Academy of Sleep Medicine 
2005). However, Sharkey and colleagues (2011) recently found that strict rise schedules could phase 
advance sleep in participants with delayed sleep phase. They did not assess sleepiness, but our findings 
suggest that also participants diagnosed with DSPD can achieve positive effects on subjective daytime 
sleepiness by gradual advanced rise times. Cole and colleagues (2002) did find a reduction in subjective 
morning sleepiness in the most delayed subjects, also in the dim light group, but the effect was larger 
after bright than dim light. Two-week treatment yielded no positive effects on objective sleepiness (AAT) 
in our study, in contrast to the findings by Rosenthal and colleagues (1990) of increased sleep latency on 
the MSLT during morning hours after bright light compared to dim light treatment. However, the AAT 
may be regarded mainly as a measure of arousal while the MSLT is a measure of sleep propensity; hence 
these two objective measures of physiological sleepiness may reflect different sleepiness modalities. In 
line with this, Alloway and colleagues (1997) found correlations between AAT and MSLT scores for a 
group of patients with narcolepsy but not for normal sleepers.  
Long-term effects of bright light and melatonin were investigated using a randomized, controlled 
design for three months. The treatment group was less sleepy measured by the KSS compared to baseline 
and maintained the positive effect after short-term treatment at the three months follow-up. On the other 
hand, subjective sleepiness measures were no different from baseline measures in the no-treatment group; 
hence the positive effect of two-week treatment was eliminated when active treatment was terminated.  
Simultaneously, the treatment group had further reduced their subjective sleepiness measured by the ESS, 
from two-week- to the three-month assessment, and reported less fatigue after three-month treatment 
compared to baseline. These findings indicate that treatment of DSPD maintained longer than two weeks 
can lead to better effects on subjective sleepiness and fatigue. This is in line with suggestions by 
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Rosenthal and colleagues (1990) that maintained treatment is necessary, because otherwise the circadian 
rhythm tends to drift back to a delayed phase in patients with DSPD. Similar to the effects on subjective 
sleepiness, the treatment group had maintained advancement of rise time and bedtime after three-month 
treatment while the no-treatment group had drifted back to delayed rise- and bedtimes.    
 
Strengths and limitations of the study 
To our knowledge, this is the first study that systematically investigates the effect on daytime function of 
bright light and melatonin in the treatment of DSPD. Previous studies of effects of bright light have 
included behavioral instructions of advanced rise times, but no studies on the effect of melatonin have 
included a gradual advancement of rise times in their treatment protocol. This study is the first to assess 
both short- and long-term effects of treatment using a controlled design combining bright light, melatonin 
and gradual advanced rise time. It is also the first controlled study investigating the effect of bright light 
and melatonin on sleepiness and performance in adolescents and young adults diagnosed with DSPD.  By 
holding the timing of the test sessions constant and in the morning, circadian confounding effects were 
reduced. Circadian variations in cognitive performance in relation to local and internal time have been 
shown for example in shift workers (Vetter et al. 2012).   
The participants in the present study were thoroughly screened for other pathologies. Hence, 
anxiety, depression or attention disorders can thus be ruled out as probable confounders to our results. 
However, the results may, on the other hand, not be directly transferable to the large number of patients 
with DSPD who suffer from co-morbid disorders (Reid et al. 2012). Furthermore, our participants scored 
somewhat above average range on self-reported school grades and intelligence, which may represent a 
bias towards relatively well-functioning patients with DSPD compared to patients that we commonly 
meet in sleep clinics, e.g. those who have dropped out of school or who are unemployed because of their 
sleep disorder.  
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The conceptualization and operationalization of sleepiness are under constant debate in the 
research literature (Horne 2010). Because of this, we included a wide range of tests measuring different 
modalities of sleepiness and cognitive functions, believed to be transferable to performance during a day 
at school or a day at work. Although improvements seen across groups on tests of cognitive functions 
after two weeks are expected due to to a practice effect (Horne 2010; Van Dongen et al. 2003), it could 
not explain group differences. In addition, we cannot rule out that the improvements seen across the two-
week groups were due to a placebo effect as all groups were active in following the instructions. 
Similarly, we cannot rule out that the differences seen across the groups in the three-month study were 
due to a placebo effect as only the treatment group received instructions and was an active group.  
 The sample size in the present study was quite large but the small group sizes in the four-armed 
two-week trial may still represent a limitation. There was a small age difference in the three-month 
follow-up groups, which possibly could account for some of the differences between the effects in the two 
groups. No other differences between background variables or baseline assessment were found; therefore 
it seems unlikely that the difference in age can explain the results.  
 As regards to the two-week treatment groups, the dim light lamps were used as placebo because 
they according to previous studies have no chronobiotic effect (Lewy et al. 1980; Rosenthal et al. 1990). 
However, more recent research has indicated that dim light at optimal times may have phase-setting 
effects (Duffy and Wright 2005). Light of 90-150 lux intensities has in recent studies been shown to have 
an effect on melatonin phase in healthy volunteers (Dijk et al. 2012), and it has been shown that long 
wavelength light has smaller effects on circadian phase than short-wavelength light (Wright et al. 2004). 
It is possible that the positive effects after the two-week assessment were due to the effect of light in all 
groups, and the behavioral instructions to gradually advance rise times in itself lead to earlier exposure to 
ambient light. Hence, what exactly is the reason why all groups improved on many variables after the 
two-week study is not clear. The fact that all groups in the two-week study (including the placebo-group) 
were active and given the same behavioral instructions, may differentiate them from pure wait-list 
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controls which has been used in other studies (Gradisar et al. 2011a). The no-treatment group in the three-
month follow-up study had become familiar with the positive effects of a gradual advancement of rise 
times, but they were not encouraged or discouraged to continue this behavior. This fact, however, may 
differentiate them from a wait-list comparison group. We did not use statistical corrections for multiple 
comparisons in the analysis of cognitive function, but the conclusions in the present study are supported 
by the consistency of results within the different functional areas. Another limitation of the study was that 
we individualized target rise times in the treatment protocol, but did not record these, and can therefore 
not report how many participants reached and/or adhered to their target rise time.     
 In the two-week study, compliance was high across all groups and the lack of differentiating 
results between the active treatment groups and placebo cannot be attributed to differences in compliance. 
For the three-month treatment group, compliance was lower but still satisfactory from a clinical 
viewpoint. If compliance was higher and all participants in the three-month treatment group complied, the 
results might have been different. Our aim was to assess the effectiveness of a treatment modality that is 
readily available in for example a primary care setting with limited time per patient. Some patients (four 
of our participants were not compliant with instructions during the 3-month treatment) with DSPD will 
likely need closer follow-up in order to adhere to treatment.   
   
Conclusion 
Gradual advancement of rise times seemed to be effective in producing positive effects on subjective 
sleepiness, fatigue and cognitive performance in short-term treatment of DSPD. However, the benefits 
from gradually advancement of rise times seem to wear off, suggesting that continuation of bright light 
and melatonin treatment is beneficial to maintain positive effects over time.  
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Figure 1. Participation flow throughout the study. 
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